Mediwound Ltd (MDWD)vsNovartis AG ADR (NVS)
MDWD
Mediwound Ltd
$14.19
-0.77%
HEALTHCARE · Cap: $182.76M
NVS
Novartis AG ADR
$153.27
+0.76%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 391453% more annual revenue ($56.69B vs $14.48M). NVS leads profitability with a 22.5% profit margin vs -180.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
MDWD
Avoid18
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.2%
Fair Value
$37.69
Current Price
$14.19
$23.50 discount
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$153.27
$60.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -63.0% — below average capital efficiency
Revenue declined 62.7%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MDWD
The strongest argument for MDWD centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : MDWD
The primary concerns for MDWD are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
MDWD profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 18/100), backed by strong 22.5% margins. MDWD offers better value entry with a 54.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mediwound Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered in Yavne, Israel.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?